{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031140","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.547591+00:00","generated_at":"2026-06-04T21:26:53.906328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29","bullets":["Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.","Cash and investments $468.3M; runway expected into H2 2026.","On track to report CLN-619 combo/monotherapy data at a medical meeting in Q2 2024.","Received FDA IND clearance for CLN-619 in multiple myeloma; exploring CLN-978 in autoimmune diseases.","CFO Jeff Trigilio to depart effective March 29, 2024, with transition support."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031140","json":"https://secwatch.observer/filing/0000950170-24-031140.json","markdown":"https://secwatch.observer/filing/0000950170-24-031140.md","text":"https://secwatch.observer/filing/0000950170-24-031140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/0000950170-24-031140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/cgem-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:26:53.906328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"616a4a325dbda65c3012e7cff516d47c3d69556e","claim":"Cullinan Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On March 14, 2024, Cullinan Oncology, Inc. announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/0000950170-24-031140-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}